Cardiff Oncology Elevates Mohindru to CEO, Appoints CFO and COO with 486,650-Share Option at $1.58
Cardiff Oncology has appointed Mani Mohindru as President and CEO, Josh Muntner as CFO and Ajay Aggarwal, MD, MBA, as COO effective April 6 and April 27 respectively. The board approved a 486,650-share inducement option grant to Muntner at a $1.58 exercise price vesting over four years.
1. Executive Leadership Appointments
Cardiff Oncology has confirmed Mani Mohindru as President and Chief Executive Officer after serving as Interim CEO, with board tenure continuing. The company also named industry veterans Josh Muntner as Chief Financial Officer effective April 6 and Ajay Aggarwal, MD, MBA, as Chief Operating Officer effective April 27 to bolster financial strategy and clinical operations.
2. Inducement Stock Option Grant
In line with Nasdaq Listing Rule 5635(c)(4), the board granted Josh Muntner non-qualified stock options for 486,650 common shares outside the 2021 Omnibus Equity Incentive Plan. The options carry a $1.58 exercise price, vesting 25% after 12 months and the remainder monthly over 36 months, contingent on continued employment.
3. Strategic Implications for Onvansertib Program
These leadership enhancements aim to accelerate the development of onvansertib in first-line RAS-mutant metastatic colorectal cancer by leveraging Muntner’s capital markets expertise and Aggarwal’s clinical research background. Strengthening executive depth is expected to support complex financings and streamline operations as the company advances its Phase 2 registrational program.